



Published in final edited form as:

J Org Chem. 2006 November 24; 71(24): 9172–9177. doi:10.1021/jo061439y.

Sigmatropic Rearrangements as Tools for Amino Acid and Peptide Modification: Application of the Allylic Sulfur Ylide Rearrangement to the Preparation of Neoglyco- and Other Conjugates

David Crich^{*}, Yekui Zou, and Franck Brebion

Department of Chemistry, University of Illinois at Chicago, 845 West Taylor Street, Chicago, Illinois 60607-7061

Abstract

Reaction of *S*-allyl cysteine derivatives, generated by the selenocysteine ligation, with rhodium carbenoids, stabilized and unstabilized, enables the attachment of diverse functionality onto cysteine residues. The reaction is successfully applied to the introduction of lipid-like residues, a fluorinated alkyl chain, and mono and disaccharides.

Introduction

Recently, we have described methods for the permanent ligation of thiols involving the coupling of either *Se*-allyl Bunte salts (*Se*-allyl selenosulfonates), or *S*-allyl *S'*-heteroaryl disulfides, with thiols to give *Se*-allyl selenosulfides or *S*-allyl disulfides, respectively, followed by a dechalcogenative 2,3-sigmatropic rearrangement to give the ligated products (Scheme 1).¹ These complementary reactions, for which all steps take place at room temperature in protic media, were illustrated by the introduction of a range of allyl and prenyl groups to cysteine and other thiols.

By virtue of the reaction mechanism these reactions afford allylic sulfides as products, thereby opening up avenues for further functionalization, one of which is the 2,3-sigmatropic rearrangement of allylic sulfur ylides as we describe here.

The 2,3-sigmatropic rearrangement of allylic sulfur ylides has been known for many years and has found widespread application in organic synthesis.² With an eye to eventual applications in the modification of peptides, proteins and other bioconjugates, for our investigation we selected the modification of this reaction popularized by Kirmse and Doyle, in which the sulfur ylide is generated by transition metal catalyzed addition of a diazoalkane to an allylic sulfide (Scheme 2).³ Our choice of the Kirmse-Doyle reaction was further guided by current interest in the deployment of transition metal-catalyzed reactions in peptide chemistry,⁴ and more particularly by the recent publication of Francis on the reaction of a stabilized vinyl diazo acetate, catalyzed by dirhodium tetracetate, with tryptophan residues in horse heart myoglobin and subtilin Carlsberg in aqueous ethylene glycol.⁵

dcrich@uic.edu.

Results and Discussion

We began with a feasibility study in which a series of diazoalkanes were allowed to react with *S*-allyl or *S*-methylallyl cysteine derivatives, obtained by the selenosulfide ligation method, in the presence of catalytic $\text{Rh}_2(\text{OAc})_4$ in dimethoxyethane at room temperature. From the results of these experiments (Table 1) it is clear that a variety of simple alkyl groups may be introduced into cysteine in this manner, with moderate yields consistent with earlier studies on simple allylic sulfides.^{3a-d,6} In each case the new stereogenic center formed as a result of the sigmatropic rearrangement was obtained as an approximately 1:1 mixture of isomers.


Attention was turned to the functionalization of a tripeptide **7** (Table 2). Given the importance of the introduction of lipids onto cysteine in peptide and protein chemistry and biochemistry, ⁷ entries 3 and 4 of Table 2 are especially noteworthy. In view of the recent interest in the fluororous tagging of peptides and proteins, attention is also called to entry 5 of Table 2.⁸

With the exception of the tryptophan case discussed below, the main byproducts from the chemistry presented here are those of dimerization of the intermediate metal carbenoids, as is typical of this type of reaction. Analysis of crude reaction mixtures by NMR spectroscopy indicates that the mass balance of the amino acid or peptide derivatives is made up largely by the unreacted substrate; insertion into the peptide or carbamate NH bond is not a major problem, as anticipated from the work of Francis.⁵

Interest in the glycosylation of cysteine residues as a means of peptide and protein glycosylation^{7a,9} led us to investigate carbohydrate-based diazoalkanes. To this end, peracetyl β -D-glucosyl and β -D-chitobiosyl diazo amides **13** and **14** were obtained from the glycosyl amines, via the tosyl hydrazones. An important feature in the design of **13** and **14** was the use of the diazoamide function rather than the much more common diazoesters. This choice was made based on the *trans*-nature of the amide bond, with its high barrier to inversion relative to the ester bond, which it was anticipated would prevent the metal carbenoid intermediate from “biting back” on the carbohydrate moiety. This supposition was borne out in practice, as the only carbohydrate-based byproducts observed upon activation with $\text{Rh}_2(\text{OAc})_4$ were those resulting from dimerization of the carbenoid, which is typical for this type of reaction.

Glucosyl diazoamide **13** was attached to allyl hexadecyl sulfide (**15**) to establish the validity of the method (Table 3) before couplings to amino acid and peptide-based sulfides were undertaken (Table 3, entries 2–5), providing access to a new class of neoglycoconjugates.¹⁰ It is especially noteworthy that, although glycoamino acids and peptides **16–20** are cysteine derivatives, the amide linkage employed opens up the possibility of the application of this chemistry, coupled with native peptide ligation¹¹ and our dechalcogenative allylation protocols,¹ as mimics of the *N*-linked glycoproteins,¹² for which new methods are constantly being sought.^{9d,e,13}

Finally, in view of the work of Francis,⁵ we briefly investigated chemoselectivity with *S*-methylallyl Boc-L-Cys-L-Ala-L-Trp-OMe¹ with a diazoketone. Literature work on the addition of Rh carbenoids to sulfides in the presence of indoles provided grounds for optimism that our chemistry would be applicable in the presence of tryptophan,¹⁴ however, complex reaction mixtures were obtained from which only two products, **21** and **22**, were obtained pure in low yield (18 and 9%, respectively). The insertion of stabilized rhodium carbenoids into the indole N-H bond, as in the formation of **22**, is a known reaction pathway,¹⁵ and is consistent with the structures proposed by Francis for reaction with protein-based tryptophan residues.⁵ At least for the present, it appears that the application of the Doyle-Kirmse reaction to *S*-allylated peptides and proteins is not compatible with the presence of tryptophan.¹⁶



Experimental Section

Phenyl diazomethane was prepared following the procedure reported by Creary.¹⁷

1-Diazo-2-heptadecanone was prepared following the procedure reported by Scott and Sumpter.¹⁸ A freshly prepared solution of diazomethane (30 mmol) in anhydrous ether (60 mL) was cooled to 0 °C and stirred at high speed. To this cooled solution, hexadecanoyl chloride (2.75 g, 10 mmol) in anhydrous ether (20 mL) was added dropwise over 20 min. The resulting reaction mixture was stirred cold for an additional 30 min and then at room temperature for 60 min. After this period of time the reaction was complete, and excess diazomethane was removed by evacuating the flask with a water aspirator pump in the hood. After the diazomethane has been removed, the remaining ethereal solution was concentrated by rotary evaporation to give crude compound. Pure 1-diazo-2-heptadecanone was obtained as yellow solid (2.61 g, 93% yield) by chromatography on silica gel using 10% ethyl acetate/hexane as an eluent. ¹H NMR: δ 5.24 (s, 1H), 2.27–2.38 (m, 2H), 1.58–1.64 (m, 2H), 1.23 (br. s, 24H), 0.86 (t, *J* = 7.0, 3H). ¹³C NMR: δ 195.4, 54.2, 41.1, 31.9, 29.7 (3C), 29.6 (2C), 29.5 (2C), 29.4 (2C), 29.2, 25.3, 22.7, 14.1. ν 2120, 2100, 1620 cm⁻¹. EIHRMS Calcd for C₁₇H₃₂N₂O [M]⁺: 280.2515, found: 280.2520.

1-Diazoundecane

1-Diazoundecane was prepared following the procedure reported by Shechter and Holton.¹⁹ Undecanal (1.36 g, 8.0 mmol) was added to stirred anhydrous hydrazine (2.56g, 80.0 mmol) at 55 °C. The reaction was continued 45 min at 55–65 °C. After the mixture had been cooled to room temperature, methylene chloride (25 mL) was added. The solution was washed with saturated aqueous sodium chloride (3 × 10 mL), dried over potassium carbonate, and concentrated under reduced pressure to a volume of 5 mL. Dimethylformamide (10 mL) was added, and remaining methylene chloride was removed by vacuum evaporation. The solution of undecanal hydrazone in dimethylformamide was cooled to -78 °C (15 min) and diluted with cold tetramethylguanidine (4 mL). Lead tetraacetate (3.90 g, 8.8 mmol) was added in 5 min, and the mixture was stirred 60 min at -78 °C. The reaction solution was diluted with cold hexane (3 × 20 mL) and extracted at -78 °C. The combined cold hexane extracts were washed with cold (-30 °C) 30% aqueous potassium hydroxide (2 × 10 mL), small pieces of dry ice were added, and the solution was then filtered to give a rose-red solution of 1-diazoundecane in hexane which was used directly in further reaction.

9-Diazo-1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorononane

4,4,5,5,6,6,7,7,8,8,9,9,9-Tridecafluorononanal (8.0 mmol) was added to stirred anhydrous hydrazine (2.56g, 80.0 mmol) at 55 °C. The reaction was continued 45 min at 55–65 °C. After the mixture had been cooled to room temperature, methylene chloride (25 mL) was added. The solution was washed with saturated aqueous sodium chloride (3 × 10 mL), dried over potassium carbonate, and concentrated under reduced pressure to a volume of 5 mL. Dimethylformamide (10 mL) was added, and remaining methylene chloride was removed by vacuum volatilization. The solution of undecylic aldehyde hydrazone in dimethylformamide was cooled to -78 °C (15 min) and diluted with cold tetramethylguanidine (4 mL). Lead tetraacetate (3.90 g, 8.8

mmol) was added in 5 min, and the mixture was stirred 60 min at $-78\text{ }^{\circ}\text{C}$. The reaction solution was diluted with cold hexane ($3 \times 20\text{ mL}$) and extracted at $-78\text{ }^{\circ}\text{C}$. The combined cold hexane extracts were washed with cold ($-30\text{ }^{\circ}\text{C}$) 30% aqueous potassium hydroxide ($2 \times 10\text{ mL}$), small pieces of dry ice were added, and the solution was then filtered to give a rose-red solution of 1-diazo-undecane in hexane which was used directly.

***N*-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyl)diazoacetamide**

To a solution of tetra-*O*-acetyl- β -D-glucopyranosylamine (695 mg, 2.0 mmol, 1.0 equiv.) and glyoxylic acid *p*-toluenesulfonylhydrazone^{2017,18} (533 mg, 2.2 mmol, 1.1 equiv.) in ice-cold THF (20 mL) was added, dropwise, DCC (454 mg, 2.2 mmol, 1.1 equiv.) in THF (10 mL). The mixture was allowed to warm to room temperature and stirring was continued over night. Then the solid was filtered off. After removal of the solvent, the filtrate was purified by flash chromatography (hexanes/EtOAc, 2:3) to afford a yellow solid (582 mg, 51% yield)

To a solution of the yellow solid (100 mg, 0.175 mmol, 1.0 equiv.) in methylene chloride (5.0 mL) was added triethylamine (0.35 mmol, 2.0 equiv.) in a nitrogen atmosphere. The mixture was stirred at room temperature over night. Then the solution was diluted with ethyl acetate (20 mL) and washed by water ($2 \times 10\text{ mL}$), brine ($2 \times 10\text{ mL}$), dried over sodium sulfate and concentrated. The remaining residue was then purified by flash chromatography (hexanes/EtOAc, 2:3) to afford the diazo compound (65 mg, 90% yield) as a viscous yellow oil. ^1H NMR: δ 6.10 (d, $J = 9.5\text{ Hz}$, 1H), 5.26–5.31 (m, 2H), 5.03 (t, $J = 9.5\text{ Hz}$, 1H), 4.88 (t, $J = 9.5\text{ Hz}$, 1H), 4.81 (s, 1H), 4.29 (dd, $J = 12.5, 4.5\text{ Hz}$, 1H), 4.06 (dd, $J = 12.5, 2.0\text{ Hz}$, 1H), 3.80–3.94 (m, 1H), 2.00–2.06 (m, 12H). ^{13}C NMR: δ 171.2, 170.7, 169.9, 169.7, 165.9, 78.5, 73.4, 72.7, 70.5, 68.2, 61.7, 48.1, 20.7 (4C). ν 2111, 1750, 1653 cm^{-1} . ESIHRMS Calcd for $\text{C}_{16}\text{H}_{21}\text{N}_3\text{O}_{10}\text{Na}$ $[\text{M}+\text{Na}]^+$: 438.1125, found: 438.1128.

***N*-(2,3,6,2',3',4',6'-Hepta-*O*-acetyl- β -cellobiosyl)-diazoacetamide**

To a solution of hepta-*O*-acetyl- β -cellobiosylamine (857 mg, 1.35 mmol, 1.0 equiv.) and glyoxylic acid *p*-toluenesulfonylhydrazone^{5,6} (360 mg, 1.49 mmol, 1.1 equiv.) in ice-cold THF (10 mL) was added, dropwise, DCC (306 mg, 1.49 mmol, 1.1 equiv.) in THF (10 mL). The mixture was allowed to warm to room temperature and stirring was continued over night. Then the solid was filtered off. After removal of the solvent, the filtrate was purified by flash chromatography (hexanes/EtOAc, 2:3) to afford a yellow solid (735 mg, 63% yield)

To a solution of the yellow solid (739 mg, 0.86 mmol, 1.0 equiv.) in methylene chloride (10 mL) was added triethylamine (1.72 mmol, 2.0 equiv.) in a nitrogen atmosphere. The mixture was stirred at room temperature over night. Then the solution was diluted with ethyl acetate (20 mL) and washed by water ($2 \times 10\text{ mL}$), brine ($2 \times 10\text{ mL}$), dried over sodium sulfate and concentrated. The remaining residue was then purified by flash chromatography (hexanes/EtOAc, 2:3) to afford the diazo compound (560 mg, 93% yield) as a yellow solid. ^1H NMR: δ 5.98 (d, $J = 9.5\text{ Hz}$, 1H), 5.22–5.26 (m, 2H), 5.12 (t, $J = 9.5\text{ Hz}$, 1H), 5.05 (t, $J = 9.5\text{ Hz}$, 1H), 4.89 (t, $J = 9.5\text{ Hz}$, 1H), 4.79 (t, $J = 9.5\text{ Hz}$, 1H), 4.78 (s, 1H), 4.48 (dd, $J = 12.5, 4.5\text{ Hz}$, 1H), 4.42 (dd, $J = 12.5, 4.5\text{ Hz}$, 1H), 4.34 (dd, $J = 12.5, 4.5\text{ Hz}$, 1H), 4.07–4.12 (m, 2H), 4.01 (dd, $J = 12.5, 2.0\text{ Hz}$, 1H), 3.72–3.76 (m, 2H), 3.62–3.65 (m, 1H), 1.95–2.12 (m, 21H). ^{13}C NMR: δ 171.1, 170.5, 170.3, 170.2, 169.5, 169.3, 169.1, 166.1, 100.6, 78.3, 76.2, 74.5, 72.9, 72.5, 71.8, 71.5, 70.7, 67.8, 62.0, 61.5, 60.4, 47.9, 20.7. ν 2111, 1751, 1654 cm^{-1} . ESIHRMS Calcd for $\text{C}_{28}\text{H}_{37}\text{N}_3\text{O}_{18}\text{Na}$ $[\text{M}+\text{Na}]^+$: 726.1970, found: 726.1981.

General Procedure for Ylide Formation and Rearrangement

To a solution of allyl sulfide compound (0.1 mmol, 1.0 equiv.) in 1,2-dimethoxyethane (5 mL), $\text{Rh}_2(\text{OAc})_4$ (0.005 mmol, 0.05 equiv.) was added, followed by addition of diazo compound in a nitrogen atmosphere. The reaction mixture was stirred vigorously at room temperature for

10 h. Then another portion of diazo compound was added, and vigorous stirring was continued at room temperature for additional 12h. The solvent was removed by evaporation, and the remaining residue was purified by flash chromatography to afford the corresponding product.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-ethoxycarbonyl-1-buten-4-yl)-*L*-cysteine ethyl ester (3)**

was prepared according to the general procedure using 10 equiv. of ethyl diazoacetate.

Colorless oil; $^1\text{H NMR}$: δ 5.72–5.77 (m, 2H), 5.37 (br. d, $J = 9.0$ Hz, 1H), 5.29 (br. d, $J = 8.0$ Hz, 1H), 5.06–5.13 (m, 4H), 4.54–4.55 (br. s, 2H), 4.16–4.23 (m, 8H), 3.40 (t, $J = 7.0$ Hz, 1H), 3.32 (dd, $J = 8.5, 6.5$ Hz, 1H), 3.03–3.14 (m, 3H), 2.91–2.95 (m, 1H), 2.56–2.59 (m, 2H), 2.38–2.43 (m, 2H), 1.44 (s, 9H), 1.43 (s, 9H), 1.27–1.29 (m, 12H). $^{13}\text{C NMR}$: δ 171.8, 170.8, 155.1, 133.9, 133.8, 118.0, 80.1, 61.8, 61.7, 61.4, 61.3, 53.4, 53.0, 46.7, 46.2, 35.8, 35.5, 33.9, 28.3, 14.2. ESIHRMS Calcd for $\text{C}_{17}\text{H}_{29}\text{NO}_6\text{S}$ [$\text{M}+\text{Na}$] $^+$: 398.1614, found: 398.1607.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-ethoxycarbonyl-2-methyl-1-buten-4-yl)-*L*-cysteine ethyl ester (4)**

was prepared according to the general procedure using 10 equiv. of ethyl diazoacetate. Colorless oil; $^1\text{H NMR}$: δ 5.35 (br. d, $J = 8.1$ Hz, 1H), 5.28 (br. d, $J = 7.8$ Hz, 1H), 4.81 (s, 2H), 4.74 (d, $J = 7.5$, 2H), 4.55 (br. s, 2H), 4.15–4.23 (m, 8H), 3.47–3.59 (m, 2H), 3.06–3.15 (m, 4H), 2.92–2.95 (m, 2H), 2.56–2.61 (m, 2H), 2.31–2.35 (m, 2H), 1.74 (s, 3H), 1.73 (s, 3H), 1.45 (s, 9H), 1.44 (s, 9H), 1.29–1.30 (m, 12H). $^{13}\text{C NMR}$: δ 172.0, 170.8, 155.2, 141.5, 141.4, 113.1, 80.1, 61.8, 61.4, 61.3, 53.4, 53.0, 45.3, 44.9, 39.6, 39.4, 33.8, 28.3, 22.3, 14.2. ESIHRMS Calcd for $\text{C}_{18}\text{H}_{31}\text{NO}_6\text{S}$ [$\text{M}+\text{H}$] $^+$: 390.1950, found: 390.1944.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-trimethylsilyl-1-buten-4-yl)-*L*-cysteine ethyl ester (5)**

was prepared according to the general procedure using 5.0 equiv. of trimethylsilyl diazomethane. Colorless oil; $^1\text{H NMR}$: δ 5.89–5.91 (m, 2H), 5.35 (br. d, $J = 8.0$ Hz, 1H), 5.29 (br. s, 1H), 5.02–5.11 (m, 4H), 4.48 (br. s, 2H), 4.17–4.22 (m, 4H), 2.86–3.03 (m, 6H), 2.48–2.50 (m, 2H), 2.29–2.32 (m, 2H), 1.92–1.93 (m, 2H), 1.46 (s, 9H), 1.44 (s, 9H), 1.26–1.29 (m, 6H), 0.15 (s, 9H), 0.14 (s, 9H). $^{13}\text{C NMR}$: δ 171.1, 155.2, 137.3, 116.4, 116.3, 80.0, 61.7, 61.6, 53.3, 53.2, 38.5, 36.2, 32.6, 32.0, 28.3, 14.2, -2.3. ESIHRMS Calcd for $\text{C}_{17}\text{H}_{33}\text{NO}_4\text{SSi}$ [$\text{M}+\text{Na}$] $^+$: 398.1798, found: 398.1793.

***N*-(*tert*-Butoxycarbonyl)-*S*-(2-methyl-5-oxo-4-icosyl)-*L*-cysteine ethyl ester (6)**

was prepared according to the general procedure using 5.0 equiv. of 1-diazo-2-heptadecanone. Pale yellow oil; $^1\text{H NMR}$: δ 5.27–5.30 (m, 2H) 4.81 (s, 2H), 4.69 (s, 2H), 4.49 (br. s, 2H), 4.21 (q, $J = 7.0$ Hz, 4H), 3.45–3.48 (m, 2H), 2.81–2.97 (m, 4H), 2.52–2.58 (m, 6H), 2.32–2.36 (m, 2H), 1.71 (s, 6H), 1.44 (s, 18H), 1.25–1.37 (m, 58 H), 0.87 (t, $J = 11.0$ Hz, 6H). $^{13}\text{C NMR}$: δ 206.3, 206.2, 170.8, 155.1, 141.6, 113.1, 80.2, 61.9, 53.2, 53.0, 51.0, 38.8, 38.1, 32.5, 29.7, 29.6, 29.4, 29.3, 29.2, 28.3, 23.9, 22.7, 22.5, 14.2. ESIHRMS Calcd for $\text{C}_{31}\text{H}_{57}\text{NO}_5\text{S}$ [$\text{M}+\text{H}$] $^+$: 556.4036, found: 556.4027.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-ethoxycarbonyl-1-buten-4-yl)-glutathione dimethyl ester (8)**

was prepared according to the general procedure using 10 equiv. of ethyl diazoacetate. Pale yellow oil; $^1\text{H NMR}$: δ 7.16 (br. d, $J = 5.0$ Hz, 2H), 6.99 (br. d, $J = 6.5$ Hz, 1H), 6.89 (br. d, $J = 6.0$ Hz, 1H), 5.72–5.75 (m, 2H), 5.35 (br. d, $J = 5.5$ Hz, 2H), 5.09–5.14 (m, 4H), 4.62–4.67 (m, 2H), 4.32–4.38 (m, 2H), 4.18–4.24 (m, 4H), 4.01–4.09 (m, 4H), 3.74 (s, 6H), 3.73 (s, 6H), 3.52 (t, $J = 7.3$ Hz, 1H), 3.44 (t, $J = 7.5$ Hz, 1H), 3.19 (dd, $J = 14.3, 6.3$ Hz, 2H), 2.94–3.02 (m, 2H), 2.59–2.65 (m, 2H), 2.44–2.48 (m, 2H), 2.32–2.38 (m, 4H), 2.16–2.21 (m, 2H), 1.93–2.01 (m, 2H), 1.43 (s, 18H), 1.24–1.29 (m, 6H). $^{13}\text{C NMR}$: δ 172.9, 172.6, 172.3, 170.4, 169.9, 155.7, 133.8, 118.1, 80.2, 61.7, 52.6, 47.2, 41.3, 35.7, 33.5, 33.0, 32.1, 28.6, 14.2. ESIHRMS Calcd for $\text{C}_{24}\text{H}_{39}\text{N}_3\text{O}_{10}\text{S}$ [$\text{M}+\text{Na}$] $^+$: 584.2254, found: 584.2255.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-phenyl-1-buten-4-yl)-glutathione dimethyl ester (9)**

was prepared according to the general procedure using 5.0 equiv. of phenyl diazomethane. Pale yellow oil; $^1\text{H NMR}$: δ 7.31–7.32 (m, 4H), 7.22–7.25 (m, 6H), 7.02 (br. s, 1 H), 6.82 (br. s,

1H), 6.67 (br. d, $J = 6.5$ Hz, 1H) 6.60 (br. d, $J = 7.0$ Hz, 1H), 5.63–5.70 (m, 2H), 5.37 (br. s, 2H), 4.95–5.04 (m, 4H), 4.32–4.45 (m, 4H), 3.86–3.98 (m, 8H), 3.73 (s, 6H), 3.72 (s, 6H), 2.83 (dd, $J = 12.0, 5.8$ Hz, 1H), 2.69–2.71 (m, 2H), 2.58–2.64 (m, 5H), 2.27–2.31 (m, 2H), 2.21–2.24 (m, 2H), 2.11–2.18 (m, 2H), 1.89–1.96 (m, 2H), 1.42 (s, 9H), 1.41 (s, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ 172.9, 172.2, 172.1, 170.6, 170.0, 169.9, 155.7, 142.0, 141.9, 135.1, 135.0, 128.7, 127.9, 127.5, 117.3, 80.2, 52.8, 52.5, 52.4, 52.2, 50.2, 50.0, 49.9, 41.3, 40.7, 40.6, 32.8, 32.2, 28.7, 28.5, 28.3. ESIHRMS Calcd for $\text{C}_{27}\text{H}_{39}\text{N}_3\text{O}_8\text{S}$ $[\text{M}+\text{Na}]^+$: 588.2356, found: 588.2364.

***N*-(*tert*-Butoxycarbonyl)-*S*-(5-oxo-4-icosyl)-glutathione dimethyl ester (10)** was prepared according to the general procedure using 5.0 equiv. of 1-diazo-2-heptadecanone. Pale yellow oil; ^1H NMR: δ 7.11–7.13 (br. s, 2H), 6.81 (br. d, $J = 6.0$ Hz, 1H), 6.80 (br. d, $J = 6.5$ Hz, 1H), 5.69–5.77 (m, 2H), 5.34–5.35 (br. d, $J = 7.0$ Hz, 2H), 5.07–5.09 (m, 4H), 4.55–4.59 (m, 2H), 4.36 (br. s, 2H), 3.95–4.09 (m, 4H), 3.74 (s, 12H), 3.44–3.49 (m, 2H), 2.80–2.90 (m, 4H), 2.55–2.62 (m, 6H), 2.32–2.46 (m, 6H), 2.14–2.17 (m, 2H), 1.91–1.97 (m, 2H), 1.51–1.57 (m, 4H), 1.42 (s, 18H), 1.16–1.28 (m, 48H), 0.85–0.88 (t, $J = 7.0$ Hz, 6H). ^{13}C NMR: δ 207.7, 207.3, 172.9, 172.3, 172.2, 170.4, 170.3, 169.9, 155.7, 134.2, 134.1, 118.1, 118.0, 80.2, 52.8, 52.7, 52.6, 52.5, 52.4, 52.2, 41.3, 39.7, 39.6, 34.5, 32.4, 32.2, 32.1, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 28.7, 28.5, 28.3, 23.9, 22.7, 14.1. ESIHRMS Calcd for $\text{C}_{37}\text{H}_{65}\text{N}_3\text{O}_9\text{S}$ $[\text{M}+\text{Na}]^+$: 750.4340, found: 750.4322.

***N*-(*tert*-Butoxycarbonyl)-*S*-(1-tetradecen-4-yl)-glutathione dimethyl ester (11)** was prepared according to the general procedure using 5.0 equiv. of 1-diazo-undecane. Pale yellow oil; ^1H NMR: δ 7.16 (br. d, $J = 5.0$ Hz, 2H), 6.84 (br. d, $J = 7.0$ Hz, 2H), 5.81–5.84 (m, 2H), 5.33 (br. d, $J = 6.5$ Hz, 2H), 5.05–5.10 (m, 4H), 4.52–4.53 (m, 2H), 4.39 (br. d, $J = 4.5$ Hz, 2H), 3.98–4.05 (m, 4H), 3.74 (s, 12H), 2.97–2.98 (m, 2H), 2.76–2.79 (m, 4H), 2.34–2.38 (m, 8H), 2.11–2.19 (m, 2H), 1.85–1.96 (m, 2H), 1.51–1.54 (m, 2H), 1.43 (s, 18H), 1.24–1.39 (m, 34H), 0.85–0.88 (m, 6H). ^{13}C NMR: δ 172.9, 172.1, 170.7, 169.9, 155.7, 135.6, 135.5, 117.3, 117.2, 80.2, 52.8, 52.7, 52.5, 52.4, 46.3, 45.9, 41.3, 39.1, 34.6, 34.2, 32.3, 32.1, 31.9, 29.6, 29.5, 29.4, 28.6, 28.3, 26.8, 26.7, 22.7, 14.1. ESIHRMS Calcd for $\text{C}_{31}\text{H}_{55}\text{N}_3\text{O}_8\text{S}$ $[\text{M}+\text{H}]^+$: 630.3788, found: 630.3773.

***N*-(*tert*-Butoxycarbonyl)-*S*-(1-tridecafluorododecen-4-yl)-glutathione dimethyl ester (12)** was prepared according to the general procedure using 5.0 equiv. of 9-diazo-1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorononane. Pale yellow oil; ^1H NMR: δ 7.11 (br. s, 2H), 6.88 (br. s, 2H), 5.74–5.77 (m, 2H), 5.45 (br. s, 2H), 5.33–5.36 (m, 2H), 5.12–5.18 (m, 4H), 4.57–4.58 (m, 1H), 4.31–4.42 (m, 2H), 3.98–4.13 (m, 4H), 3.75 (s, 12H), 3.29–3.32 (m, 2H), 3.04–3.23 (m, 4H), 2.74–2.95 (m, 4H), 2.33–2.51 (m, 4H), 2.17–2.20 (m, 2H), 1.89–2.16 (m, 4H), 1.44 (s, 9H), 1.45 (s, 9H). ^{13}C NMR: δ 172.8, 171.9, 171.4, 169.9, 155.6, 133.4, 133.2, 118.4, 118.2, 80.7, 52.9, 52.7, 52.5, 45.8, 41.4, 39.5, 34.9, 34.3, 32.4, 32.2, 31.7, 29.7, 29.3, 28.8, 28.3, 28.2, 27.8, 24.6. F^{19} NMR: δ -8.3, -41.7, -49.5, -50.5, -50.9, -53.7. ESIHRMS Calcd for $\text{C}_{29}\text{H}_{38}\text{F}_{13}\text{N}_3\text{O}_8\text{S}$ $[\text{M}+\text{H}]^+$: 836.2245, found: 836.2247.

***N*-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyl)-(2-hexadecylsulfanyl)-4-pentenamide (16)** was prepared according to the general procedure using 5.0 equiv. of *N*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-diazoacetamide. Colorless oil; ^1H NMR: δ 7.21–7.30 (m, 2H), 5.66–5.79 (m, 2H), 5.30 (t, $J = 9.5$ Hz, 2H), 5.19–5.23 (m, 2H), 5.01–5.33 (m, 6H), 4.96–5.00 (m, 2H), 4.28–4.32 (m, 2H), 4.05–4.08 (m, 2H), 3.79–3.82 (m, 2H), 3.25–3.28 (m, 2H), 2.38–2.49 (m, 6H), 2.17 (s, 6H), 2.07 (s, 6H), 2.03 (s, 6H), 2.02 (s, 6H), 1.52–1.55 (m, 4H), 1.24–1.33 (m, 54H), 0.87 (t, $J = 7.0$ Hz, 6H). ^{13}C NMR: δ 172.5, 172.4, 170.6, 170.4, 170.0, 169.6, 133.9, 133.8, 118.2, 117.9, 78.4, 73.6, 72.9, 72.8, 70.3, 68.2, 61.7, 49.5, 49.4, 36.5, 36.2, 31.9, 31.5, 31.4, 29.7, 29.6, 29.5, 29.4, 29.2, 29.0, 28.9, 22.7, 20.7, 20.6, 14.2. ESIHRMS Calcd for $\text{C}_{35}\text{H}_{59}\text{N}_3\text{O}_{10}\text{S}$ $[\text{M}+\text{Na}]^+$: 708.3758, found: 708.3732.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-*N*-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyl)aminocarbonyl-1-buten-4-yl)-L-cysteine ethyl ester (17)** was prepared according to the general procedure using 5.0 equiv. of *N*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl) diazoacetamide. Pale yellow oil; $^1\text{H NMR}$: δ 7.41 (br. d, $J = 8.5$ Hz, 1H), 7.27 (br. s, 1H), 5.55–5.74 (m, 2H), 5.64–5.74 (m, 1H), 5.50 (br. d, $J = 7.5$ Hz, 1H), 5.19–5.30 (m, 4H), 4.98–5.12 (m, 6H), 4.43 (br, 2H), 4.25–4.30 (m, 2H), 4.15–4.21 (m, 4H), 4.02–4.11 (m, 4H), 3.77–3.81 (m, 2H), 3.30–3.33 (m, 2H), 3.09 (br. d, $J = 13.0$ Hz, 1H), 2.94–2.97 (m, 1H), 2.68–2.74 (m, 2H), 2.60–2.65 (m, 1H), 2.48–2.54 (m, 1H), 2.33–2.40 (m, 2H), 1.98–2.05 (m, 24H), 1.47 (s, 9H), 1.46 (s, 9H), 1.21–1.27 (m, 6H). $^{13}\text{C NMR}$: δ 171.8, 171.6, 171.2, 170.7, 170.6, 170.4, 169.9, 169.5, 169.4, 155.5, 155.4, 133.9, 133.4, 118.2, 118.1, 80.5, 80.4, 73.6, 72.9, 72.7, 70.3, 68.1, 68.0, 62.0, 61.9, 61.7, 61.5, 60.4, 53.0, 49.8, 48.0, 36.2, 35.8, 34.2, 33.7, 28.4, 21.1, 20.7, 20.6, 14.2. ESIHRMS Calcd for $\text{C}_{29}\text{H}_{44}\text{N}_2\text{O}_{14}\text{S}$ $[\text{M}+\text{Na}]^+$: 699.2406, found: 699.2410.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-*N*-(2,3,6,2',3',4',6'-hepta-*O*-acetyl- β -cellobiosyl)aminocarbonyl-1-buten-4-yl)-L-cysteine ethyl ester (18)** was prepared according to the general procedure using 5.0 equiv. of *N*-(2,3,6,2',3',4',6'-hepta-*O*-acetyl- β -cellobiosyl) diazoacetamide. Pale yellow oil; $^1\text{H NMR}$: δ 7.26 (br. d, $J = 9.0$ Hz, 1H), 7.13 (br. d, $J = 9.0$ Hz, 1H), 5.59–5.61 (m, 2H), 5.46 (br. d, $J = 6.6$ Hz, 1H), 5.21–5.28 (m, 3H), 5.03–5.19 (m, 10H), 4.88–4.92 (m, 4H), 4.40–4.49 (m, 6H), 4.33–4.35 (m, 2H), 4.08–4.19 (m, 8H), 3.98–4.01 (m, 2H), 3.62–3.71 (m, 6H), 3.26–3.31 (m, 2H), 3.03–3.08 (m, 1H), 2.91–2.96 (m, 1H), 2.68–2.73 (m, 1H), 2.59–2.66 (m, 1H), 2.45–2.51 (m, 1H), 2.31–2.39 (m, 2H), 1.95–2.09 (m, 42H), 1.45 (s, 9H), 1.42 (s, 9H), 1.21–1.27 (m, 6H). $^{13}\text{C NMR}$: δ 171.6, 171.4, 170.8, 170.7, 170.6, 170.5, 170.2, 169.4, 169.3, 169.0, 155.3, 133.7, 133.4, 118.2, 118.1, 100.7, 80.378.3, 78.2, 76.2, 74.5, 72.9, 72.2, 72.1, 72.0, 71.5, 70.5, 67.8, 62.0, 61.9, 61.6, 60.4, 53.5, 53.1, 49.8, 48.4, 36.2, 35.8, 34.1, 33.5, 28.4, 21.1, 20.8, 20.7, 20.5, 14.2. ESIHRMS Calcd for $\text{C}_{41}\text{H}_{60}\text{N}_2\text{O}_{22}\text{S}$ $[\text{M}+\text{H}]^+$: 965.3431, found: 965.3424.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-*N*-(2,3,4,6-Tetra-*O*-acetyl- β -D-glucopyranosyl)aminocarbonyl-1-buten-4-yl)-glutathione dimethyl ester (19)** was prepared according to the general procedure using 5.0 equiv. of *N*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)- diazoacetamide. Pale yellow oil; $^1\text{H NMR}$: δ 7.69 (br. d, $J = 8.5$ Hz, 2H), 7.35 (br. s, 2H), 7.01 (br. d, $J = 7.5$ Hz, 2H), 5.73–5.76 (m, 2H), 5.35 (br. s, 2H), 5.26–5.31 (m, 4H), 4.99–5.14 (m, 6H), 4.82 (br. s, 2H), 4.32–4.40 (m, 4H), 4.03–4.14 (m, 4H), 3.82–3.87 (m, 2H), 3.73–3.79 (m, 12H), 3.63 (br. s, 2H), 2.96–3.31 (m, 4H), 2.62–2.64 (m, 2H), 2.52–2.54 (m, 2H), 2.35–2.37 (m, 4H), 2.00–2.19 (m, 28H), 1.43 (s, 9H), 1.42 (s, 9H). $^{13}\text{C NMR}$: δ 172.9, 172.3, 172.1, 170.8, 170.6, 170.3, 170.0, 169.6, 155.6, 133.9, 133.8, 118.2, 80.2, 78.3, 73.9, 73.1, 70.6, 70.5, 68.2, 68.1, 61.7, 60.4, 52.8, 52.6, 52.1, 52.0, 49.2, 45.4, 41.3, 41.2, 36.0, 35.2, 33.8, 32.6, 31.9, 28.3, 24.0, 21.0, 20.8. ESIHRMS Calcd for $\text{C}_{36}\text{H}_{54}\text{N}_4\text{O}_{18}\text{S}$ $[\text{M}+\text{H}]^+$: 885.3046, found: 885.3059.

***N*-(*tert*-Butoxycarbonyl)-*S*-(4-*N*-(2,3,6,2',3',4',6'-hepta-*O*-acetyl- β -cellobiosyl)aminocarbonyl-1-buten-4-yl)-glutathione dimethyl ester (20)** was prepared according to the general procedure using 5.0 equiv. of *N*-(2,3,6,2',3',4',6'-hepta-*O*-acetyl- β -cellobiosyl) diazoacetamide. Pale yellow oil; $^1\text{H NMR}$: δ 7.55 (br. d, $J = 9.1$ Hz, 1H), 7.28 (br. d, $J = 7.0$ Hz, 1H), 6.98 (br. d, $J = 8.1$ Hz, 1H), 5.62–5.71 (m, 1H), 5.33 (br. d, $J = 8.1$ Hz, 1H), 5.20–5.27 (m, 4H), 5.10–5.14 (m, 3H), 5.03–5.07 (m, 4H), 4.89–4.92 (m, 4H), 4.61–4.68 (br. s, 1H), 4.48–4.52 (m, 5H), 4.34–4.37 (m, 2H), 4.25 (br. s, 1H), 4.03–4.12 (m, 8H), 3.71–3.76 (m, 10H), 3.64–3.66 (m, 3H), 3.12 (br. s, 1H), 3.01 (br. s, 1H), 2.52–2.61 (m, 1H), 2.50–2.51 (m, 1H), 2.35–2.37 (m, 2H), 1.98–2.13 (m, 21H), 1.42 (s, 9H). $^{13}\text{C NMR}$: δ 173.0, 172.3, 171.5, 170.6, 170.5, 170.3, 170.2, 169.9, 169.8, 169.3, 169.0, 155.6, 133.9, 133.8, 118.0, 100.6, 80.3, 78.1, 76.4, 74.9, 73.2, 73.1, 71.9, 71.8, 71.6, 70.5, 67.8, 61.8, 61.7, 61.5, 52.9, 52.6, 52.5, 52.4, 46.4, 41.4, 35.1, 32.8, 32.0, 28.3, 20.8. ESIHRMS Calcd for $\text{C}_{48}\text{H}_{70}\text{N}_4\text{O}_{26}\text{S}$ $[\text{M}+\text{H}]^+$: 1151.4072, found: 1151.4071.

***N*-(*tert*-Butoxycarbonyl)-*S*-(2-methyl-5-oxo-4-icosyl)-*L*-cysteinyl-*L*-alanyl-*L*-tryptophan methyl ester (21)** was prepared according to the general procedure using 5.0 equiv. of 1-diazo-2-heptadecanone, which was contaminated by approximately 10% of **22**. ¹H NMR: (400 MHz, CDCl₃) δ 8.68 (s, 1H), 8.59 (s, 1H), 7.51 (d, *J* = 7.7 Hz, 1H), 7.50 (d, *J* = 7.7 Hz, 1H), 7.34 (m, 2H), 7.16 (m, 2H), 7.09 (m, 2H), 7.00 (s, 1H), 6.98 (s, 1H), 6.80–6.67 (m, 4H), 5.28 (m, 1H), 5.15 (m, 1H), 4.89–4.80 (m, 4H), 4.73 (s, 1H), 4.70 (s, 1H), 4.47–4.37 (m, 2H), 4.20–4.10 (m, 2H), 3.694 (s, 3H), 3.692 (s, 3H), 3.53 (m, 2H), 3.37–3.23 (m, 4H), 2.74–2.73 (m, 4H), 2.62–2.50 (m, 6H), 2.38–2.31 (m, 2H), 1.74 (s, 3H), 1.73 (s, 3H), 1.63–1.56 (m, 4H), 1.47 (s, 18H), 1.31 (d, *J* = 7.1 Hz, 6H), 1.30–1.20 (m, 52H), 0.88 (t, *J* = 7.0 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 207.6, 207.4, 172.04, 171.99, 171.1, 170.13, 170.07, 155.6, 141.6, 141.5, 136.3, 127.5, 127.4, 123.23, 123.19, 122.06, 122.04, 113.3, 111.38, 111.33, 109.5, 79.8, 54.0, 53.4, 53.1, 52.7, 52.4, 50.9, 50.8, 48.9, 39.1, 39.0, 38.0, 37.9, 32.4, 32.2, 31.9, 29.68, 29.65, 29.5, 29.4, 29.3, 29.2, 28.3, 27.4, 27.3, 23.9, 22.7, 22.4, 17.5, 17.4, 14.1. ESIHRMS Calcd for C₄₄H₇₁N₄O₇S [M+H]⁺: 799.5038, found: 799.5038; Calcd for C₄₄H₇₀N₄O₇SNa [M+Na]⁺: 821.4858, found: 821.4560.

***N*-(*tert*-Butoxycarbonyl)-*S*-(2-methylallyl)-*L*-cysteinyl-*L*-alanyl-*L*-*N*_ω-(2-oxo-heptadecyl)-tryptophan methyl ester (22)** was prepared according to the general procedure using 5.0 equiv. of 1-diazo-2-heptadecanone. ¹H NMR (400 MHz, CDCl₃) δ 7.50 (d, *J* = 7.7 Hz, 1H), 7.20 (m, 1H), 7.14–7.10 (m, 2H), 6.90 (s, 1H), 6.84 (br. d, *J* = 7.7 Hz, 1H), 6.59 (br. d, *J* = 7.6 Hz, 1H), 5.29 (m, 1H), 4.93–4.79 (m, 4H), 4.45 (quint, *J* = 7.4 Hz, 1H), 4.14 (m, 1H), 3.68 (s, 3H), 3.33 (d, *J* = 5.6 Hz, 2H), 3.03 (d, *J* = 13.4 Hz, 1H), 2.96 (d, *J* = 13.4 Hz, 1H), 2.72 (dd, *J* = 13.7, 5.9 Hz, 1H), 2.65 (dd, *J* = 13.7, 6.7 Hz, 1H), 2.35 (t, *J* = 7.4 Hz, 2H), 1.77 (s, 3H), 1.56 (m, 2H), 1.44 (s, 9H), 1.32 (d, *J* = 7.1 Hz, 3H), 1.30–1.20 (m, 26H), 0.88 (d, *J* = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 206.4, 171.8, 171.3, 170.4, 140.7, 136.6, 128.1, 127.6, 122.4, 119.8, 119.0, 114.5, 109.6, 108.9, 80.4, 55.2, 53.8, 52.6, 52.5, 48.9, 39.4, 33.1, 31.9, 29.7, 29.5, 29.4, 29.1, 28.3, 27.3, 23.4, 22.7, 20.6, 18.0, 14.1. FABHRMS Calcd for C₄₄H₇₀N₄O₇SNa [M+Na]⁺: 821.4863, found: 821.4859.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements


We thank the NIH (GM 62160) for partial support of this work.

References

- (a) Crich D, Krishnamurthy V, Hutton TK. *J Am Chem Soc* 2006;128:2544. [PubMed: 16492032] (b) Crich D, Brebion F, Krishnamurthy V. *Org Lett* 2006;8:3593. [PubMed: 16869668]
- Trost, BM.; Melvin, SM. *Sulfur Ylides*. Academic Press; New York: 1975. (b) Vedejs E. *Acc Chem Res* 1984;17:358.
- (a) Kirmse W, Kapps M. *Chem Ber* 1968;101:994. (b) Doyle MP, Tamblyn WH, Bagheri V. *J Org Chem* 1981;46:4094. (c) Doyle MP, Griffin JH, Chinn MS, van Leusen D. *J Org Chem* 1984;49:1917. (d) Doyle MP, Tamblyn WH, Bagheri V. *J Org Chem* 1981;46:5094. (e) Ando W, Yagihara T, Kondo S, Nakayama K, Yamato H, Nakaido S, Migita T. *J Org Chem* 1971;36:1732. Doyle, MP.; McKervey, MA.; Ye, T. *Modern Catalytic Methods for Organic Synthesis with Diazo compounds*. Wiley; New York: 1998. Aggarwal, V.; Richardson, J. *Science of Synthesis: Compounds with Two Carbon-Heteroatom Bonds*. Padwa, A., editor. 27. Thieme; Stuttgart: 2004. p. 21 (h) Li AH, Dai LX, Aggarwal VK. *Chem Rev* 1997;97:2341. [PubMed: 11848902] (i) Doyle MP, Forbes DC. *Chem Rev* 1998;98:911. [PubMed: 11848918] (j) Hodgson DM, Pierard FYTM, Stupp PA. *Chem Soc Rev* 2001;30:50.


4. (a) McFarland JM, Francis MF. *J Am Chem Soc* 2005;127:13490. [PubMed: 16190700] (b) Tilley DS, Francis MB. *J Am Chem Soc* 2006;128:1080. [PubMed: 16433516] (c) van Maarseveen JH, Reek JNH, Back JW. *Angew Chem Int Ed* 2006;45:1841. (d) Dibowski H, Schmidtchen FP. *Angew Chem Int Ed* 1998;37:476. (e) Antos JM, Francis MB. *Curr Op Chem Biol* 2006;10:253.
5. Antos JM, Francis MF. *J Am Chem Soc* 2004;126:10256. [PubMed: 15315433]
6. (a) Carter DS, Van Vranken DL. *Tetrahedron Lett* 1999;40:1617. (b) Aggarwal VK, Ferrara M, Hainz R, Spey SE. *Tetrahedron Lett* 1999;40:8923.
7. (a) Pachamuthu K, Schmidt RR. *Chem Rev* 2006;106:160. [PubMed: 16402775] (b) Clarke S. *Ann Rev Biochem* 1992;61:355. [PubMed: 1497315] (c) Schelhaas M, Nägele E, Kuder N, Bader B, Kuhlmann J, Wittinghofer A, Waldmann H. *Chem Eur J* 1999;5:1239. (d) Schelhaas M, Glomsda S, Hänslér M, Jakubke HD, Waldmann H. *Angew Chem Int Ed* 1996;35:106. (e) Brown MJ, Milano PD, Lever DC, Epstein WW, Poulter CD. *J Am Chem Soc* 1991;113:3176. (f) Pachamuthu K, Zhu X, Schmidt RR. *J Org Chem* 2005;70:3720. [PubMed: 15845014]
8. Brittain SM, Ficarro SB, Brock A, Peters EC. *Nature Biotechnology* 2005;23:463.
9. (a) Gamblin DP, Garnier P, van Kasteren S, Oldham NJ, Fairbanks AJ, Davis BG. *Angew Chem Int Ed* 2004;43:828. (b) Gamblin DP, Garnier SJ, Ward NJ, Oldham AJ, Fairbanks AJ, Davis BG. *Org Biomol Chem* 2003;1:3642. [PubMed: 14649893] (c) Doores KJ, Gamblin DP, Davis BG. *Chem Eur J* 2006;12:656. (d) Davis BG. *Chem Rev* 2002;102:579. [PubMed: 11841255] (e) Peri F, Nicotra F. *Chem Comm* 2004:623. (f) Ohnishi Y, Ichikawa M, Ichikawa Y. *Biorg Med Chem Lett* 2000;10:1289. (g) Jobron L, Hummel G. *Org Lett* 2000;2:2265. [PubMed: 10930259] (h) Cohen SB, Halcomb RL. *Org Lett* 2001;3:405. [PubMed: 11428025] (i) Knapp S, Myers DS. *J Org Chem* 2002;67:2995. [PubMed: 11975558] (j) Zhu XM, Pachamuthu K, Schmidt RR. *Org Lett* 2004;6:1083. [PubMed: 15040728] (k) Zhu XM, Schmidt RR. *Chem Eur J* 2004;10:875. (l) Thayer DA, Yu HN, Galan MC, Wong CH. *Angew Chem Int Ed* 2005;44:4596. (m) Bertozzi CR, Kiessling LL. *Science* 2001;291:2357. [PubMed: 11269316] (n) Galonic DP, Ide ND, van der Donk W, Gin DY. *J Am Chem Soc* 2005;127:7359. [PubMed: 15898784]
10. Roy, R. *Carbohydrate Chemistry*. Boons, G-J., editor. Blackie; London: 1998. p. 243 Lee, YT.; Lee, RC., editors. *Neoglycoconjugates: Preparation and Applications*. Academic; San Diego: 1994. (c) Ichikawa Y, Matsukawa Y, Isobe M. *J Am Chem Soc* 2006;128:3934. [PubMed: 16551100] (d) Ladmiral V, Mantovani G, Clarkson GJ, Cauet S, Irwin JL, Haddleton DM. *J Am Chem Soc* 2006;128:4823. [PubMed: 16594719] (e) Hotha S, Kashyap S. *J Org Chem* 2006;71:364. [PubMed: 16388660]
11. Dawson PE, Kent SBH. *Ann Rev Biochem* 2000;69:923. [PubMed: 10966479]
12. (a) Dwek RA, Butters TD. *Chem Rev* 2002;102:283. (b) Varki A. *Glycobiology* 1993;3:97. [PubMed: 8490246] Lehmann, J. *Carbohydrates: Structure and Biology*. Thieme; Stuttgart: 1998.
13. (a) He Y, Hinklin RJ, Chang J, Kiessling L. *Org Lett* 2004;6:4479. [PubMed: 15548055] (b) Grandjean C, Boutonnier A, Guerreiro C, Fournier JM, Mulard LA. *J Org Chem* 2005;70:7123. [PubMed: 16122231] (c) Wen S, Guo Z. *Org Lett* 2001;3:3773. [PubMed: 11700135] (d) Mizuno M, Goto K, Miura T. *Chem Lett* 2005;34:426. (e) Kaneshiro CM, Michael K. *Angew Chem Int Ed* 2006;45:1077. (f) Mandal M, Dudkin VY, Geng X, Danishefsky SJ. *Angew Chem Int Ed* 2004;43:2557. (g) Lin H, Walsh CT. *J Am Chem Soc* 2004;126:13998. [PubMed: 15506762] (h) Tanaka H, Iwata Y, Takahashi D, Adachi M, Takahashi T. *J Am Chem Soc* 2005;127:1630. [PubMed: 15700984] (i) Doores KJ, Mimura Y, Dwek RA, Rudd PM, Elliott T, Davis BG. *Chem Commun* 2006:1401. (j) Liu H, Wang L, Brock A, Wong CH, Schulz PG. *J Am Chem Soc* 2003;125:1702. [PubMed: 12580587] (k) Brik A, Yang YY, Ficht S, Wong CH. *J Am Chem Soc* 2006;128:5626. [PubMed: 16637616] (l) Hang HC, Bertozzi CR. *Acc Chem Res* 2001;34:727. [PubMed: 11560472]
14. Nyong AM, Rainier JD. *J Org Chem* 2005;70:746. [PubMed: 15651836]
15. (a) Salim M, Capretta A. *Tetrahedron* 2000;56:8063. (b) Gibe R, Kerr MA. *J Org Chem* 2002;67:6247. [PubMed: 12182672]
16. It can be similarly inferred that the reaction of rhodium carbenoids with protein-based tryptophan described by Francis is likely not compatible with the presence of nucleophilic sulfur as in cysteine and methionine.
17. Creary X. *J Am Chem Soc* 1980;102:1502.
18. Scott LT, Sumpter CA. *Org Synth* 1990;69:180.
19. Holton TL, Shechter H. *J Org Chem* 1995;60:4725.

20. (a) House HO, Blankley CJ. *J Org Chem* 1968;33:53. (b) Ouhia A, Rene L, Badet B. *Tetrahedron Lett* 1992;33:5509.




Ar = 2-pyridyl, 5-nitro-2-pyridyl, 2-benzothiazolyl

Scheme 1.
Dechlorogenative Allylic Selenosulfide and Disulfide Ligations



Scheme 2.
Reaction of metal carbenoids with allyl thio ethers



Scheme 3.
Preparation of diazo amides **13** and **14**

Table 1

Reaction of carbenoids with cysteine derivatives.

1: R = H
2: R = Me

3-6

	Cmpd	Diazo Deriv	Product (% yield)
1	1	ethyl diazoacetate	<p>3 (53)</p>
2	2	ethyl diazoacetate	<p>4 (42)</p>
3	1	TMSdiazomethane	<p>5 (57)</p>
4	2	Me(CH ₂) ₁₄ COCHN ₂	<p>6 (52)</p>
















Table 2Reaction of carbenoids with *S*-allyl glutathione.

	R	Product (% Yield)
1	CO ₂ Et	8 (45)
2	C ₆ H ₅	9 (45)
3	CO(CH ₂) ₁₄ Me	10 (38)
4	(CH ₂) ₉ Me ^a	11 (35)
5	(CH ₂) ₂ (CF ₂) ₅ CF ₃ ^a	12 (32)

^a Diazo precursors to **11** and **12** were prepared from the hydrazones with Pb(OAc)₄ and were used immediately.

Table 3

Rh₂(OAc)₄ Catalyzed Glycosylation

	Substrate	Diazo Compound	Product (%yield)
1	 15	 13	 16(52)
2	 1	 13	 17(48)
3	 1	 14	 18(54)
4	 7	 13	 19(34)
5	 7	 14	 20(41)